Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (992) Arrow Down
Filter Results: (992) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (992)
    • People  (4)
    • News  (257)
    • Research  (615)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (397)

Show Results For

  • All HBS Web  (992)
    • People  (4)
    • News  (257)
    • Research  (615)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (397)
← Page 27 of 992 Results →
  • 02 Mar 2007
  • What Do You Think?

What Is the Government’s Role in US Health Care?

Newman), the high cost of new technology, artificial restrictions on the supply of drugs (Sergey Mirkiin) and healthcare providers (David Stahl and Michael Robbins), the size and complexity of the problem itself (James Sullivan),... View Details
Keywords: by Jim Heskett; Health
  • June 2024
  • Article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Keywords: Health Care and Treatment; Valuation; Cost vs Benefits; Society
Citation
Read Now
Related
Shafrin, Jason, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington, and Richard Willke. "Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices." Forum of Health Economics and Policy 27, no. 1 (June 2024): 29–116.
  • August 2003 (Revised August 2024)
  • Case

Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment

By: Regina E. Herzlinger and John McDonough
Many health care innovations appear successful; but fail. This is the first case in the Innovating Health Care course that investigates how to create successful health care innovations. It is part of the first module in the course. This module focuses on how to... View Details
Keywords: Three Pillars; Industry Analysis; Health Care and Treatment; Innovation and Invention; Innovation and Management; Medical Specialties; Health Industry
Citation
Educators
Purchase
Related
Herzlinger, Regina E., and John McDonough. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Case 304-009, August 2003. (Revised August 2024.)
  • 21 Feb 2018
  • Research & Ideas

When a Competitor Abandons the Market, Should You Advance or Retreat?

SolStock In late 2016 drug maker Eli Lilly announced it would stop research on the Alzheimer's drug solanezumab after results proved disappointing over three trials. For competitors such as Biogen, Merck,... View Details
Keywords: by Rachel Layne; Pharmaceutical; Health
  • 30 Jun 2022
  • HBS Case

Peloton Changed the Exercise Game. Can the Company Push Through the Pain?

got a lot of levers to pull.” Despite the risk, Dolan believes Peloton does appear to have a future. “It’s not like they’re a high-tech company, wondering if a drug will get FDA approval,” Dolan says. “No surprises are coming down the... View Details
Keywords: by Lane Lambert; Media & Broadcasting; Health; Bicycle
  • Web

Policies, Rules & Guidelines | About

flights; the purpose of this policy is to help clarify acceptable use and safety of UAS on or above the HBS campus. Drug & Alcohol Policy Harvard Business School’s policy on drugs and alcohol reflects our... View Details
  • 25 Jul 2023
  • Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

With Hepatitis C running rampant in Egypt in 2012, Clifford Samuel, then of California-based Gilead Sciences, convened a series of urgent meetings with Egyptian government officials, doctors, and patients. His goal? To make Gilead’s lifesaving Hepatitis C View Details
Keywords: by Esther Schrader; Pharmaceutical; Health
  • 22 Feb 2024
  • News

Combat-Tested Cancer Coaching

Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Hi, this is Dan Morrell, host of Skydeck. When Kathy Giusti (MBA 1985) was diagnosed with multiple myeloma in 1996, she was overwhelmed. It was the pre-Internet era, with limited available information, but... View Details
  • Article

Cybersecurity Features of Digital Medical Devices: An Analysis of FDA Product Summaries

By: Ariel Dora Stern, William J. Gordon, Adam B. Landman and Daniel B. Kramer
Objectives:
To more clearly define the landscape of digital medical devices subject to U.S. Food and Drug Administration (FDA) oversight, this analysis leverages publicly available regulatory documents to characterise the prevalence and trends of software and... View Details
Keywords: Digital; Medicine; FDA; Health Care and Treatment; Applications and Software; Safety; Cybersecurity; Medical Devices and Supplies Industry
Citation
Read Now
Related
Stern, Ariel Dora, William J. Gordon, Adam B. Landman, and Daniel B. Kramer. "Cybersecurity Features of Digital Medical Devices: An Analysis of FDA Product Summaries." BMJ Open 9, no. 6 (June 2019).
  • 19 Dec 2017
  • First Look

New Research and Ideas, December 19, 2017

Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53633 Characterizing the Drug Development Pipeline for Precision Medicines By: Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern... View Details
Keywords: Carmen Nobel
  • Web

General Management - Faculty & Research

20–33. Market Dynamics and Moral Dilemmas: Novo Nordisk's Weight Loss Drugs By: Joseph L. Badaracco June 2025 | Teaching Note | Faculty Research Teaching Note for HBS Case No. 324-114. Citation Purchase Related Badaracco, Joseph L.... View Details
  • 15 Nov 2022
  • Book

Stop Ignoring Bad Behavior: 6 Tips for Better Ethics at Work

In 1995, Purdue Pharma began selling a powerful and addictive opioid drug called OxyContin. The company was aware that the drug, which was marketed to doctors as a safe way to manage chronic pain, was a potent narcotic that could quickly... View Details
Keywords: by Pamela Reynolds
  • January–February 2023
  • Article

Data-Driven COVID-19 Vaccine Development for Janssen

By: Dimitris Bertsimas, Michael Lingzhi Li, Xinggang Liu, Jennings Xu and Najat Khan
The COVID-19 pandemic has spurred extensive vaccine research worldwide. One crucial part of vaccine development is the phase III clinical trial that assesses the vaccine for safety and efficacy in the prevention of COVID-19. In this work, we enumerate the first... View Details
Keywords: COVID-19; Health Testing and Trials; Forecasting and Prediction; AI and Machine Learning; Research; Pharmaceutical Industry
Citation
Find at Harvard
Purchase
Related
Bertsimas, Dimitris, Michael Lingzhi Li, Xinggang Liu, Jennings Xu, and Najat Khan. "Data-Driven COVID-19 Vaccine Development for Janssen." INFORMS Journal on Applied Analytics 53, no. 1 (January–February 2023): 70–84.
  • Research Summary

Overview

By: Joshua Lev Krieger
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is... View Details
  • 01 Sep 2023
  • News

Solving for Z

With nearly 20 years of experience as a senior human resources executive, Matthew Breitfelder (MBA 2002) has seen a lot of change in the corporate talent space. But what’s happening now looks like a tectonic generational shift. From his perch as global head of human... View Details
Keywords: Alexander Gelfand; Illustrations by Doug Chayka; Administration of Human Resource Programs; Government
  • January 2016 (Revised July 2018)
  • Case

Cyberdyne: A Leap to the Future

By: Doug J. Chung and Mayuka Yamazaki
Cyberdyne Inc. was a Japanese technology venture that wanted to commercialize a hybrid assistive limb (HAL). HAL was a robotic exoskeleton system for people who had difficulty walking due to nervous system disabilities resulting from stroke, spinal cord injury (SCI),... View Details
Keywords: Go-to-market Strategy; Pricing; Sales Channel; Technological Innovation; Marketing; Sales; Distribution; Strategy; Medical Devices and Supplies Industry
Citation
Educators
Purchase
Related
Chung, Doug J., and Mayuka Yamazaki. "Cyberdyne: A Leap to the Future." Harvard Business School Case 516-072, January 2016. (Revised July 2018.)
  • 07 Feb 2024
  • News

The Sound of Success

A groundbreaking gene therapy developed by Akouos, Inc., a precision genetic medicine company founded in 2016 by Emmanuel (Manny) Simons (MBA 2012), has enabled an 11-year-old boy from Morocco to hear sounds for the first time. According to a recent New York Times... View Details
  • 25 Mar 2016
  • HBS Seminar

Curtis Keith, Harvard University, Blavatnik Biomedical Accelerator

  • Web

Skydeck - Alumni

revolutionize drug development along the way Bridging the Gap Global Citizen Year founder Abby Falik (MBA 2008) on why kids need to find their purpose before freshman year Cold Call Horror Stories Alumni relive the School's most... View Details
  • 13 Jul 2023
  • News

The Network Effect

Karan Mathur (left) and Dina Model (Illustration by Gisela Goppel) Karan Mathur (left) and Dina Model (Illustration by Gisela Goppel) When Dina Model and Karan Mathur (both MBA 2015) met through mutual friends during their first year at HBS, neither was envisioning a... View Details
  • ←
  • 27
  • 28
  • …
  • 49
  • 50
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.